IGC vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IGC Pharma exhibits severe financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from catastrophic operating margins (-1517.80%) and a significant year-over-year revenue decline of 53.60%. While the balance sheet shows low debt, the valuation is disconnected from fundamentals with a Price/Sales ratio of 28.60. Despite a speculative analyst target price of $4.12, the historical earnings track record and bearish technical trend suggest a high risk of capital loss.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IGC vs MRK: Head-to-Head Comparison
This page compares IGC Pharma, Inc. (IGC) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.